Factbox-Court challenges to Medicare drug price negotiation plan

(Reuters) – The U.S. government on Tuesday selected the first 10 drugs, including the big-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer, that will be subject to the first-ever Medicare price negotiations, part of President Joe Biden’s Inflation Reduction Act (IRA) that drugmakers and industry groups have challenged in court.

At least eight lawsuits were filed between June and late August seeking to block the price negotiation, arguing that the law and forced price cuts would violate various amendments to the U.S. constitution. The following are key details of the lawsuits:

Company Date Location Drugs named

filed in lawsuit

as likely to

be affected

by IRA

Merck & Co June 6 U.S. District Court Diabetes

for the District of drugs

Columbia Januvia and

Janumet,

cancer

treatment

Keytruda

The U.S. June 9 U.S. District Court NA

Chamber of for the Southern

Commerce District Of Ohio

Western Division

Bristol Myers June 16 U.S. District Court Blood

Squibb for the District of thinner

New Jersey Eliquis,

cancer

therapy

Opdivo

Astellas July 14 U.S. District Court Prostate

Pharma For The Northern cancer drug

District of Illinois, Xtandi,

Eastern Division Myrbetriq

for treating

overactive

bladder

Johnson & July 18 U.S. District Court Blood

Johnson for the District of thinner

New Jersey Xarelto

Pharmaceutica June 21 U.S. District Court NA

l Research For the Western

and District Of Texas

Manufacturers Austin Division

of America

Boehringer Aug 18 U.S. District Court Diabetes

Ingelheim for the District Of drug

Connecticut Jardiance

AstraZeneca Aug 25 U.S. District Court Cancer drug

For the District Of Lynparza,

Delaware blood

disorder

treatment

Soliris

Source: Read Full Article